Bellevue Life Sciences Acquisition Corp.
BLAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.10 | -2.95 | 279.37 |
| FCF Yield | -4.23% | -1.01% | -0.00% | -0.00% |
| EV / EBITDA | -15.14 | 21.70 | 479.19 | 345.07 |
| Quality | ||||
| ROIC | 114.27% | -2.26% | -3.04% | -0.83% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.08 | -2.03 | 0.12 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -167.22% | -19,233.41% | -818.66% | 98.06% |
| Safety | ||||
| Net Debt / EBITDA | -0.48 | -0.00 | 5.57 | 1.69 |
| Interest Coverage | 81.95 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |